RxDoctor Payments Data

Akshay Dave, MD

Family Medicine · Gibbstown, NJNPI 1770563074

Payments from drug & device makers

$923in general payments, 2019–2025

Across 47 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nestle Healthcare Nutrition Inc.$170
  • Teva Pharmaceuticals USA, Inc.$166
  • Otsuka America Pharmaceutical, Inc.$141
  • SK Life Science, Inc.$76
  • UCB, Inc.$76
  • Sumitomo Pharma America, Inc.$63
  • plus $231 from 10 others

What the payments were for

  • Food & beverage$923100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$923 in reported general payments places this provider in the 65th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$7,506
Medicare patients
25
Services billed
54

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine14$151,149
LinzessLinaclotide55$30,840
ProliaDenosumab14$25,317
VraylarCariprazine Hcl18$16,566
OzempicSemaglutide11$11,022
Divalproex Sodium40$10,684
Carbamazepine43$5,533
Esomeprazole Magnesium55$3,291
Famotidine71$2,749
Levetiracetam60$2,177
FenofibrateFenofibrate Nanocrystallized43$1,478
Metoprolol Succinate45$929
Levothyroxine Sodium89$739
Aripiprazole35$669
Lacosamide12$572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$166$151,14914 claims
AmgenProlia$15$25,31714 claims
Lilly USA, LLCOlanzapine$25$18117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Gibbstown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →